Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Relay Therapeutics, Inc. (RLAY) was the issuer for which SB Investment Advisers (UK) Limited, SoftBank Vision Fund (AIV M2) L.P., and SVF Pauling (Cayman) Limited reported shared beneficial ownership of 21,904,963 shares, or 9.9% of the common stock, as of September 30, 2026. The ownership figure was based on 220,959,470 common shares outstanding as of October 30, 2026.
Key Figures
Shared beneficial ownership:21,904,963 sharesPercentage of class:9.9%Common shares outstanding:220,959,470 shares
3 metrics
Shared beneficial ownership21,904,963 sharesReported by each reporting person as of September 30, 2026
Percentage of class9.9%Reported beneficial ownership as of September 30, 2026
Common shares outstanding220,959,470 sharesAs of October 30, 2026
Key Terms
beneficial ownership, alternative investment fund manager
2 terms
beneficial ownershipregulatory
"Amount beneficially owned"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
alternative investment fund managerregulatory
"SBIA UK has been appointed as alternative investment fund manager"
An alternative investment fund manager is a firm or individual that runs pooled investment vehicles that buy non-traditional assets—such as private equity, hedge funds, real estate, commodities or infrastructure—rather than publicly traded stocks and bonds. Investors care because these managers seek higher or different types of returns and risks, charge specialized fees, and often use less liquid strategies, so they can materially affect portfolio risk, return and access to opportunities.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How many Relay Therapeutics (RLAY) shares did the reporting persons beneficially own?
The three reporting persons each reported shared beneficial ownership of 21,904,963 shares, equal to 9.9% of the common stock, as of September 30, 2026.
Who holds the Relay Therapeutics shares reported by SoftBank?
SVF Pauling (Cayman) Limited is the record holder and is a wholly owned subsidiary of SoftBank Vision Fund (AIV M2) L.P. SB Investment Advisers (UK) Limited was appointed as the fund’s alternative investment fund manager and is exclusively responsible for decisions related to its investments, including voting and disposal.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 1)
Relay Therapeutics, Inc.
(Name of Issuer)
Common Stock, par value $0.001 per share
(Title of Class of Securities)
75943R102
(CUSIP Number)
09/30/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
75943R102
1
Names of Reporting Persons
SB Investment Advisers (UK) Limited
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED KINGDOM
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
21,904,963.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
21,904,963.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
21,904,963.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
9.9 %
12
Type of Reporting Person (See Instructions)
CO
SCHEDULE 13G
CUSIP Number(s):
75943R102
1
Names of Reporting Persons
SoftBank Vision Fund (AIV M2) L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
21,904,963.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
21,904,963.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
21,904,963.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
9.9 %
12
Type of Reporting Person (See Instructions)
PN
SCHEDULE 13G
CUSIP Number(s):
75943R102
1
Names of Reporting Persons
SVF Pauling (Cayman) Ltd
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
CAYMAN ISLANDS
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
21,904,963.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
21,904,963.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
21,904,963.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
9.9 %
12
Type of Reporting Person (See Instructions)
CO
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
Relay Therapeutics, Inc.
(b)
Address of issuer's principal executive offices:
60 Hampshire Street, Cambridge, MA 02139
Item 2.
(a)
Name of person filing:
Each of the following is hereinafter individually referred to as a "Reporting Person" and collectively as the "Reporting Persons." This statement is filed on behalf of:
SB Investment Advisers (UK) Limited ("SBIA UK")
SoftBank Vision Fund (AIV M2) L.P. ("AIV M2")
SVF Pauling (Cayman) Limited
(b)
Address or principal business office or, if none, residence:
The address for SBIA UK is 1st Floor, 77 Grosvenor Street, London W1K 3JR, United Kingdom.
The address for AIV M2 is 1521 Concord Pike, Wilmington, DE 19803. The address for SVF
Pauling (Cayman) Limited is c/o Walkers, 190 Elgin Avenue, George Town, Grand Cayman, Cayman Islands KY1-9008.
(c)
Citizenship:
SBIA UK is organized under the laws of England and Wales. AIV M2 is organized under the laws of the State of Delaware. SVF Pauling (Cayman) Limited is organized under the laws of the Cayman Islands.
(d)
Title of class of securities:
Common Stock, par value $0.001 per share
(e)
CUSIP No.:
75943R102
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
The ownership information presented herein represents beneficial ownership of Common Stock as of September 30, 2026, based upon 220,959,470 shares of Common Stock outstanding as of October 30, 2026, as disclosed in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 4, 2026.
SVF Pauling (Cayman) Limited is the record holder of the securities reported herein.
SVF Pauling (Cayman) Limited is a wholly owned subsidiary of AIV M2. SBIA UK has been appointed as alternative investment fund manager ("AIFM") of AIV M2. SBIA UK is authorized and regulated by the UK Financial Conduct Authority and is exclusively responsible for making all decisions related to the acquisition, structuring, financing, voting and disposal of AIV M2's investments. As a result of these relationships, each of the Reporting Persons may be deemed to share beneficial ownership of the securities reported herein.
(b)
Percent of class:
9.9%
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
0
(ii) Shared power to vote or to direct the vote:
21,904,963
(iii) Sole power to dispose or to direct the disposition of:
0
(iv) Shared power to dispose or to direct the disposition of:
21,904,963
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
Not Applicable
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
Not Applicable
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.